Literature DB >> 36074496

Evolution of Early-Phase Anticancer Drug Investigations in China.

Shuhang Wang1, Yue Yu1, Yale Jiang1, Huishan Zhang2, Peiwen Ma1, Gang Liu3, Ning Li1.   

Abstract

Entities:  

Year:  2022        PMID： 36074496      PMCID： PMC9459900          DOI： 10.1001/jamaoncol.2022.3856

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  2 in total

1.  Clinical trials and drug approvals continue to accelerate in China.

Authors:  Mai Wang
Journal:  Lancet Oncol       Date:  2017-05-25       Impact factor: 41.316

2.  Anticancer drug R&D landscape in China.

Authors:  Shen Zhao; Hongyun Zhao; Cheng Lv; Jifang Gong; Jian Zhang; Wenfeng Fang; Jin Li; Xichun Hu; Yi Ba; Binghe Xu; Yanqiao Zhang; Yun Fan; Kunyan Li; Xiaoyuan Chen; Zhimin Yang; Lin Shen; Li Zhang
Journal:  J Hematol Oncol       Date:  2020-05-13       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.